Quotient Sciences Quotient Sciences

X
[{"orgOrder":0,"company":"Edge Pharma","sponsor":"ANI Pharmaceuticals Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Edge Pharma Completes Supplier Agreement with ANI Pharmaceuticals, Inc","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"June 2020","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved"},{"orgOrder":0,"company":"Edge Pharma","sponsor":"Evio Labs","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"EVIO, Inc. Enters Into Letter of Intent to Acquire Leading Edge Pharms, Inc.","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"July 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"}]

Find Clinical Drug Pipeline Developments & Deals by Edge Pharma

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            LEP has formulated a line of products including CANNAVERA™, a family of topical pain relief products currently pending for over-the-counter (OTC) registration with the FDA.

            Lead Product(s): Cannabis Sativa,Eugenia Caryophyllus Flower Oil,Rosmarinus Officinalis Leaf Extract

            Therapeutic Area: Neurology Product Name: Cannavera

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Evio Labs

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition July 12, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Edge Pharma has signed an agreement with ANI Pharmaceuticals to market the company's FDA approved Vancomycin Hydrochloride for Oral Solution USP, a generic equivalent to Vancocin®.

            Lead Product(s): Vancomycin Hydrochloride

            Therapeutic Area: Gastroenterology Product Name: Vancomycin Hydrochloride-Generic

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: ANI Pharmaceuticals Inc

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement June 25, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY